- Many Virginia insurance plans cover Wegovy, but coverage varies by specific plan and employer
- Prior authorization is typically required and involves documenting BMI and health conditions
- Wegovy’s cardiovascular indication opens an alternative coverage pathway for eligible patients
- PEAK verifies your insurance before your first visit and handles the prior authorization process
Important GLP-1 safety warning: Wegovy carries a boxed warning for thyroid C-cell tumors. Avoid use in patients with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2.
The short answer
Many Virginia insurance plans do cover Wegovy (semaglutide 2.4mg) — but coverage varies significantly by plan. There is no simple yes-or-no answer that applies to every patient in the state. Your coverage depends on your specific insurer, plan type, employer decisions, and whether you meet the clinical criteria for prior authorization.
The good news is that coverage has expanded substantially over the past two years. More insurers are adding Wegovy to their formularies, and the FDA’s cardiovascular indication has created new pathways to approval. The key is understanding your specific plan and working through the prior authorization process correctly — which is exactly what the PEAK team does for every patient before treatment begins.
Insurance coverage for Wegovy in Virginia is not a question of if — it is a question of which pathway works for your specific plan.
Major Virginia insurers and Wegovy coverage
Here is a breakdown of how the largest insurers in Virginia are currently handling Wegovy coverage. Keep in mind that even within the same insurer, coverage can differ dramatically based on your specific plan.
Anthem Blue Cross Blue Shield
Anthem is one of the largest insurers in Virginia, and many of their plans cover Wegovy with prior authorization. Coverage is most common in employer-sponsored plans that include anti-obesity medication benefits. Anthem typically requires documentation of BMI, comorbidities, and previous weight management attempts. Their prior authorization process is generally well-defined and PEAK has significant experience handling it.
Aetna
Aetna’s coverage for Wegovy varies widely by plan type. Some fully-insured commercial plans include coverage, while others explicitly exclude weight loss medications. Self-funded employer plans through Aetna depend entirely on the employer’s benefit design. Aetna plans that do cover Wegovy typically require step therapy and prior authorization with clinical documentation.
Cigna
Cigna has been expanding Wegovy coverage across many of its plan offerings. Several Cigna commercial plans in Virginia now include anti-obesity medications on their formulary, though tier placement and cost-sharing vary. Prior authorization is required, and Cigna’s criteria generally align with FDA-approved indications — BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity.
UnitedHealthcare (UHC)
UnitedHealthcare coverage for Wegovy varies considerably by plan. Some UHC commercial and employer plans cover Wegovy with prior authorization, while others maintain weight loss medication exclusions. UHC’s Oxford plans may have different coverage criteria than standard UHC plans. Verification of your specific plan is essential.
TRICARE
TRICARE covers office visits at PEAK for eligible beneficiaries, but medication coverage varies by TRICARE plan. TRICARE Prime and Select may cover Wegovy with prior authorization for beneficiaries who meet clinical criteria. However, TRICARE for Life (TFL) does not cover weight loss medications — TFL patients would need to self-pay for the medication itself. Given Virginia’s significant military population, this is relevant for many patients in the Hampton Roads area. PEAK has extensive experience navigating TRICARE’s authorization process for patients on plans that do include medication coverage.
Sentara Health Plans
As a major regional insurer in Virginia, Sentara Health Plans’ coverage for Wegovy is plan-dependent. Some Sentara plans include anti-obesity medications while others do not. Coverage is more common in plans offered through larger employer groups. Prior authorization requirements apply when coverage is available.
Optima Health
Optima Health, another prominent Virginia-based insurer, has variable coverage for Wegovy across its plan offerings. Coverage depends on the specific plan purchased by the employer or individual. Where coverage exists, prior authorization is required with standard clinical documentation.
Insurance coverage is not determined at the insurer level alone. Two people with Anthem BCBS can have completely different Wegovy coverage based on their employer’s plan design, the specific product they purchased, and their plan year. The only way to know for certain is to verify your specific plan — which PEAK does for every patient.
Employer-sponsored vs. marketplace vs. government plans
The type of insurance plan you have matters as much as the insurer name on your card. Coverage for Wegovy differs significantly across plan categories, even when administered by the same insurance company.
Employer-sponsored plans
Most Virginians with commercial insurance have employer-sponsored coverage. These plans fall into two categories:
- Fully-insured plans follow the insurer’s standard formulary and coverage policies. If the insurer covers Wegovy, your plan likely does too (subject to prior authorization).
- Self-funded plans are designed by the employer, who decides which medications to cover. An employer using Anthem as their administrator can choose to exclude weight loss medications entirely, even though Anthem’s standard formulary includes them. This is the most common reason patients are surprised by a coverage denial.
If you have employer-sponsored insurance, the employer’s benefit design is the single most important factor in determining your Wegovy coverage. Your HR department or benefits administrator can often clarify whether anti-obesity medications are included in your plan.
ACA marketplace plans
Affordable Care Act marketplace plans in Virginia have variable coverage for weight loss medications. While the ACA requires coverage of preventive services, anti-obesity medications have not universally been classified as essential health benefits. Some marketplace plans include coverage, but many do not. Check your plan’s formulary or contact the insurer directly.
Medicare
Traditional Medicare (Parts A and B) does not cover Wegovy for weight loss. However, Wegovy’s FDA-approved cardiovascular indication has opened potential coverage under Medicare Part D for patients with established cardiovascular disease. Medicare Advantage plans may offer additional coverage depending on the plan sponsor. This is an evolving area — coverage rules are shifting as the cardiovascular indication gains broader acceptance.
Medicaid (Virginia)
Virginia Medicaid coverage for Wegovy is limited. While some state Medicaid programs have begun covering anti-obesity medications, Virginia’s Medicaid formulary has historically excluded them. Patients on Medicaid should verify current coverage, as policies are subject to change.
Note: PEAK accepts commercial insurance and TRICARE. We do not accept Medicare or Medicaid.
Prior authorization requirements
Even when your insurance plan covers Wegovy, you will almost certainly need prior authorization (PA) before coverage begins. Prior authorization is your insurer’s process of reviewing your clinical information to confirm that the medication is medically appropriate before they agree to pay for it.
What is prior authorization?
Prior authorization requires your prescribing provider to submit documentation to your insurance company demonstrating that you meet the clinical criteria for Wegovy. The insurer then reviews this documentation and issues an approval or denial, typically within 5 to 15 business days. Some insurers offer expedited review for urgent requests.
Typical documentation requirements
While specific criteria vary by insurer, most prior authorization requests for Wegovy require:
- BMI documentation. A BMI of 30 or greater (obesity), or a BMI of 27 or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia.
- Comorbidity documentation. Medical records showing weight-related health conditions including type 2 diabetes, hypertension, obstructive sleep apnea, cardiovascular disease, or dyslipidemia.
- Previous weight management attempts. Many insurers require evidence that you have tried supervised lifestyle modifications (diet and exercise programs) before approving medication. The required duration varies — typically 3 to 6 months of documented effort.
- Clinical notes. Progress notes from your provider documenting the medical necessity of Wegovy for your specific situation.
What increases your chances of approval
Successful prior authorization comes down to thorough, accurate documentation that aligns precisely with your insurer’s criteria. Factors that strengthen an approval:
- Complete and current BMI measurements with documented weight history
- Clearly documented comorbidities with supporting lab work or diagnostic records
- Detailed records of previous weight management attempts, including dates and outcomes
- A provider who understands your insurer’s specific PA criteria and submits documentation accordingly
- Submitting all required documentation at once, rather than in piecemeal fashion
Our team submits prior authorization requests as part of every patient’s onboarding process. We know the specific documentation requirements for each major Virginia insurer, and we compile your clinical information to meet their exact criteria before submission. This is not something you need to handle on your own.
The cardiovascular coverage pathway
In March 2024, the FDA approved Wegovy for a second indication: reducing the risk of major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) in adults with established cardiovascular disease who are overweight or obese. This approval was based on the landmark SELECT trial, which demonstrated a 20% reduction in major cardiovascular events.
This cardiovascular indication has created a significant new pathway for insurance coverage — one that can bypass weight loss medication exclusions entirely.
How the cardiovascular pathway works
Many insurance plans that exclude anti-obesity or weight loss medications still cover cardiovascular medications and preventive therapies. When Wegovy is prescribed for cardiovascular risk reduction rather than weight management, it may fall under a different benefit category entirely — one that is not subject to weight loss exclusions.
To qualify for this pathway, patients typically need:
- Established cardiovascular disease (history of heart attack, stroke, or peripheral arterial disease)
- BMI of 27 or greater
- Documentation from a cardiologist or primary care provider supporting the cardiovascular indication
This pathway is specifically for patients with established cardiovascular disease — not for general cardiovascular risk factors like high blood pressure or high cholesterol alone. Your PEAK clinician will evaluate whether this indication applies to your clinical situation and, if so, pursue this coverage route on your behalf.
What if you are denied?
A denial is not necessarily the end of the road. Many initial denials can be overturned on appeal, particularly when the original submission was incomplete or did not precisely match the insurer’s criteria.
Common denial reasons
- Plan exclusion. The plan explicitly excludes weight loss medications. This is the hardest denial to overturn, though the cardiovascular pathway may offer an alternative.
- Insufficient documentation. The prior authorization submission did not include all required clinical information. This is the most common — and most fixable — reason for denial.
- Step therapy requirements. The insurer requires you to try other medications first (such as oral semaglutide or other anti-obesity drugs) before approving Wegovy.
- BMI does not meet criteria. The documented BMI does not meet the plan’s threshold, or comorbidities were not adequately documented.
- Missing lifestyle modification history. The insurer requires evidence of supervised weight management attempts that was not included in the submission.
The appeal process
If you are denied, you have the right to appeal. The appeal process typically involves:
- Review the denial letter. The letter must specify the exact reason for denial and cite the plan provisions or clinical criteria that were not met.
- Submit additional documentation. Address the specific deficiency identified in the denial. If the issue was incomplete records, gather and submit the missing information.
- Peer-to-peer review. Your provider can request a conversation with the insurer’s medical director to discuss your case directly. This is often the most effective step in overturning a denial.
- External review. If internal appeals are exhausted, Virginia law provides for independent external review of coverage denials.
If your initial prior authorization is denied, our team reviews the denial reason, strengthens the documentation, and submits the appeal on your behalf. We also conduct peer-to-peer reviews with insurance medical directors when needed. You should not have to fight your insurance company alone.
Manufacturer savings programs
Novo Nordisk, the manufacturer of Wegovy, offers a savings program that can significantly reduce your out-of-pocket costs — even when you have insurance coverage.
Novo Nordisk Wegovy Savings Card
The manufacturer savings card is available to commercially insured patients and can reduce copays significantly for eligible patients. Key details:
- Eligibility. You must have commercial insurance (not Medicare, Medicaid, or other government-funded programs). Your plan does not need to cover Wegovy — the savings card can be used alongside insurance or as a standalone benefit for commercially insured patients.
- Typical savings. Eligible patients may pay a reduced copay per 28-day supply, depending on their plan’s coverage. Maximum savings limits apply per fill and per calendar year.
- How to activate. Your PEAK care team can help you determine eligibility and activate the savings card as part of your treatment onboarding. The card is presented at the pharmacy alongside your insurance card.
- Limitations. The savings card does not apply to government-insured patients (Medicare, Medicaid, TRICARE). Terms and maximum savings amounts are subject to change by Novo Nordisk.
Manufacturer savings programs are updated regularly. Eligibility criteria, savings amounts, and program availability can change without notice. PEAK stays current on all available savings programs and will advise you on the most current options at the time of your treatment.
How to check your coverage
If you want to investigate your coverage on your own before contacting PEAK, here is how to do it effectively.
Call the number on the back of your card
The most reliable way to check coverage is to call your insurance company’s member services line. When you call, ask these specific questions:
- “Is Wegovy (semaglutide 2.4mg injection) on my plan’s formulary?” This tells you whether the medication is covered at all.
- “What tier is Wegovy placed on?” Tier placement determines your copay or coinsurance amount. Lower tiers mean lower out-of-pocket costs.
- “Is prior authorization required?” Almost always yes, but confirm and ask for the specific criteria.
- “Does my plan have a weight loss medication exclusion?” Some plans exclude all anti-obesity medications regardless of medical necessity.
- “What are the step therapy requirements?” Some plans require you to try other medications before Wegovy will be approved.
Write down the reference number for your call and the name of the representative. This documentation can be valuable if there are later disputes about what you were told.
Or let PEAK verify for you
Working through insurance is complex, and the information you receive from a member services call is not always complete or accurate. At PEAK, we verify your Wegovy coverage as part of our intake process — before your first visit. Our team contacts your insurer directly, reviews your specific plan’s formulary and PA requirements, and gives you a clear picture of your coverage and expected costs before you begin treatment.
You should know exactly what your insurance covers before you start treatment — not after you receive a surprise bill.
